| ■ 영문 제목 : Live Cell Encapsulation Market Size, Share & Trends Analysis Report By Polymer Type (Natural, Synthetic), By Application (Drug Delivery, Cell Transplantation), By Method, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MR113
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 2월
■ 페이지수 : 150
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 바이오
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Grand View Research사의 본 조사 보고서는 글로벌 생세포 캡슐화 시장 규모가 2023년부터 2030년 사이에 CAGR 3.97% 증가하여, 2030년에는 286.5백만 달러에 이를 것으로 예상하고 있습니다. 본 자료는 글로벌 생세포 캡슐화 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 폴리머 종류별 (천연, 합성) 분석, 방법별 (마이크로 캡슐화, 매크로 캡슐화, 나노 캡슐화) 분석, 용도별 (약물 전달, 재생 의료, 세포 이식, 기타) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카) 분석, 경쟁 현황 등의 내용을 수록하고 있습니다. 덧붙여 본 리포트는 AUSTRIANOVA, MERCK KGAA, SPHERE FLUIDICS LIMITED, VIACYTE, INC., BLACKTRACE HOLDINGS LTD (DOLOMITE MICROFLUIDICS), BIO INX, LIVING CELL TECHNOLOGIES LIMITED, SIGILON THERA, DIATRANZ OTSUKA LTD 등의 기업 정보가 포함되어 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・글로벌 생세포 캡슐화 시장 규모 : 폴리머 종류별
- 천연 생세포 캡슐화의 시장 규모
- 합성 생세포 캡슐화의 시장 규모
・글로벌 생세포 캡슐화 시장 규모 : 방법별
- 마이크로 캡슐화의 시장 규모
- 매크로 캡슐화의 시장 규모
- 나노 캡슐화의 시장 규모
・글로벌 생세포 캡슐화 시장 규모 : 용도별
- 약물 전달에 사용되는 생세포 캡슐화의 시장 규모
- 재생 의료에 사용되는 생세포 캡슐화의 시장 규모
- 세포 이식에 사용되는 생세포 캡슐화의 시장 규모
- 기타 용도에 사용되는 생세포 캡슐화의 시장 규모
・글로벌 생세포 캡슐화 시장 규모 : 지역별
- 북미의 생세포 캡슐화 시장 규모
- 유럽의 생세포 캡슐화 시장 규모
- 아시아 태평양의 생세포 캡슐화 시장 규모
- 중남미의 생세포 캡슐화 시장 규모
- 중동과 아프리카의 생세포 캡슐화 시장 규모
・경쟁 현황 |
■ 보고서 개요Live Cell Encapsulation Market Growth & Trends
The global live cell encapsulation market size is projected to reach USD 286.5 million by 2030, registering a CAGR of 3.97% during the forecast period, according to a new report by Grand View Research, Inc. Increasing adoption of live cell encapsulation in regenerative medicine, rising public-private investments in cell & gene therapies, and the growing significance of live cell encapsulation for therapeutic purposes are key factors driving the industry. Furthermore, major advantages associated with live cell encapsulation of a drug or treatment system include easy administration, the possibility to control the accurate release rate of a drug over time, and the provision of desired, pre-programmed drug release anticipated to boost the industry growth over the study period. Increasing public-private funding & investments in cell and gene therapies are projected to drive the market during the forecast period.
For instance, in June 2022, Immuneel Therapeutics raised series A funding of USD 15 million to develop affordable cell and gene therapy for cancer patients in India. In October 2022, Vita Therapeutics received series B funding of USD 31 million for the development of cell therapies for neuromuscular diseases and cancers. Hence, increasing funding may boost R&D activities, ultimately increasing the demand for live cell encapsulation techniques. The COVID-19 infection affected multiple organs leading to an increase in research studies on chronic or acute organ damage caused by the virus. Tissue engineering strategies including live cell encapsulation techniques are used to treat the damages. For instance, the live cell encapsulation technique with alginate was used to deliver hormones to the body for female reproductive system damages caused due to COVID-19 infection.
Thus, the COVID-19 pandemic had a positive impact on the industry. Moreover, live cell encapsulation technology has proven to be a suitable treatment strategy for diseases, such as heart failure, diabetes, cancer, anemia, or the central nervous system. For instance, encapsulated islet cells are stem cells enclosed in a protective capsule to treat type 1 diabetes. Encapsulated islet cells prevent low and high sugar levels from occurring, and eliminate the need for daily blood glucose tests & take insulin daily. Hence, the growing significance of live cell encapsulation for therapeutic purposes is expected to drive the adoption of these methods. Furthermore, increasing strategic initiatives, such as partnerships and clinical trials on cell encapsulation technology, by operating players are expected to drive the industry.
For instance, in February 2021, ViaCyte, Inc. announced the initiation of phase 2 clinical study of encapsulated cell therapy to treat type 1 diabetes. In addition, in November 2022, Nanoscribe and BIO INX expanded their partnership with the launch of novel biocompatible high-resolution bioink HYDROBIO INX for live cell encapsulation. On the other hand, the high product manufacturing costs may hamper the industry during the forecast years. Live cell encapsulation technology must fulfill strict requirements, such as biosafety, performance, biocompatibility, stability, purity, and retrievability, leading to high production costs. Such high costs may not be affordable for small- and medium-sized companies and hamper market growth to a certain extent. In addition, the limited availability of high-quality raw materials may hinder growth. However, industry players are continuously developing high-quality raw materials, reducing the production cost of the technology.
Live Cell Encapsulation Market Report Highlights
• The natural polymers segment held the largest share in 2022 owing to its advantages, such as low toxicity, renewability, biocompatibility, flexibility to modification, and biodegradability
• The microencapsulation method segment accounted for the largest share in 2022 due to the benefits offered by microencapsulation, including pre-programmed drug-release profiles, easy administration, and the ability of the technique to control the release rate of a fused drug over periods (hours to months)
• The drug delivery application segment dominated the industry in 2022 owing to the potential application of drug delivery to treat various diseases, such as cancer, tuberculosis, diabetes, and rheumatoid arthritis, in the form of tablets, capsules, or parenteral dosage forms
• North America held the largest revenue share in 2022. The large share can be attributed to established healthcare infrastructure, increased per capita healthcare expenditure, and rising funding & investments in cell and gene therapies space in the region
■ 보고서 목차Table of Contents
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market Analysis
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing Adoption Of Live Cell Encapsulation In Regenerative Medicine
3.2.1.2 Rising Public-Private Investments In Cell And Gene Therapies
3.2.1.3 Growing Significance Of Live Cell Encapsulation For Therapeutic Purposes
3.2.2 Market Restraint Analysis
3.2.2.1 High Product Manufacturing Costs
3.2.2.2 Limited Market Avalibity Of High-Quality Raw Materials
3.3 Penetration &Growth Prospect Mapping
3.4 Live Cell Encapsulation Market – Porter’s Analysis
3.5 Live Cell Encapsulation Market – Swot Analysis
3.6 Covid-19 Impact Analysis
Chapter 4 Polymer Type Business Analysis
4.1 Live Cell Encapsulation Market-Polymer Type Movement Analysis
4.2 Natural Polymers
4.2.1 Global Natural Polymers Market, 2018 – 2030 (USD Million)
4.2.2 Alginate
4.2.2.1 Global Alginate Market, 2018 – 2030 (USD Million)
4.2.3 Chitosan
4.2.3.1 Global Chitosan Market, 2018 – 2030 (USD Million)
4.2.4 Cellulose
4.2.4.1 Global Cellulose Market, 2018 – 2030 (USD Million)
4.2.5 Others
4.2.5.1 Global Others Market, 2018 – 2030 (USD Million)
4.3 Synthetic Polymers
4.3.1 Global Synthetic Polymers Market, 2018 – 2030 (USD Million)
Chapter 5 Method Business Analysis
5.1 Live Cell Encapsulation Market-Method Movement Analysis
5.2 Microencapsulation
5.2.1 Global Microencapsulation Market, 2018 – 2030 (USD Million)
5.3 Macroencapsulation
5.3.1 Global Macroencapsulation Market, 2018 – 2030 (USD Million)
5.4 Nanoencapsulation
5.4.1 Global Nanoencapsulation Market, 2018 – 2030 (USD Million)
Chapter 6 Application Business Analysis
6.1 Live Cell Encapsulation Market-Application Movement Analysis
6.2 Drug Delivery
6.2.1 Global Drug Delivery Market, 2018 – 2030 (USD Million)
6.3 Regenerative Medicine
6.3.1 Global Regenerative Medicine Market, 2018 – 2030 (USD Million)
6.4 Cell Transplantation
6.4.1 Global Cell Transplantation Market, 2018 – 2030 (USD Million)
6.5 Others
6.5.1 Global Others Market, 2018 – 2030 (USD Million)
Chapter 7 Regional Business Analysis
7.1 Live Cell Encapsulation Market: Regional Movement Analysis
7.2 North America
7.2.1 Swot Analysis
7.2.1.1 North America Live Cell Encapsulation Market, 2018 – 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 Competitive Scenario
7.2.2.3 U.S. Live Cell Encapsulation Market, 2018 – 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Key Country Dynamics
7.2.3.2 Competitive Scenario
7.2.3.3 Canada Live Cell Encapsulation Market, 2018 – 2030 (USD Million)
7.3 Europe
7.3.1 Swot Analysis
7.3.1.1 Europe Live Cell Encapsulation Market Estimates And Forecast, 2018-2030, (Usd Million)
7.3.2 U.K.
7.3.2.1 Key Country Dynamics
7.3.2.2 Competitive Scenario
7.3.2.3 U.K. Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.3 Germany
7.3.3.1 Key Country Dynamics
7.3.3.2 Competitive Scenario
7.3.3.3 Germany Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 Competitive Scenario
7.3.4.3 France Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.5 Italy
7.3.5.1 Key Country Dynamics
7.3.5.2 Competitive Scenario
7.3.5.3 Italy Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.6 Spain
7.3.6.1 Key Country Dynamics
7.3.6.2 Competitive Scenario
7.3.6.3 Spain Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Competitive Scenario
7.3.7.3 Denmark Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Competitive Scenario
7.3.8.3 Sweden Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.3.9 Norway
7.3.9.1 Key Country Dynamics
7.3.9.2 Competitive Scenario
7.3.9.3 Norway Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.4 Asia Pacific
7.4.1 Swot Analysis
7.4.1.1 Asia Pacific Vacuum Blood Collection Tube, 2018-2030, (Usd Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Competitive Scenario
7.4.2.3 Japan Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 Competitive Scenario
7.4.3.3 China Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 Competitive Scenario
7.4.4.3 India Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Competitive Scenario
7.4.5.3 Australia Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.4.6 Thailand
7.4.6.1 Key Country Dynamics
7.4.6.2 Competitive Scenario
7.4.6.3 Thailand Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.4.7 South Korea
7.4.7.1 Key Country Dynamics
7.4.7.2 Competitive Scenario
7.4.7.3 South Korea Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.5 Latin America
7.5.1 Swot Analysis
7.5.1.1 Latin America Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Competitive Scenario
7.5.2.3 Brazil Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Competitive Scenario
7.5.3.3 Mexico Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.5.4 Argentina
7.5.4.1 Key Country Dynamics
7.5.4.2 Competitive Scenario
7.5.4.3 Argentina Live Cell Encapsulation Market, 2018-2030, (Usd Million)
7.6 Middle East & Africa (Mea)
7.6.1 Swot Analysis
7.6.1.1 Mea Live Cell Encapsulation Market Estimates And Forecast, 2018-2030, (Usd Million)
7.6.2 South Africa
7.6.2.1 Key Country Dynamics
7.6.2.2 Competitive Scenario
7.6.2.3 South Africa Live Cell Encapsulation Market Estimates And Forecast, 2018-2030, (Usd Million)
7.6.3 Saudi Arabia
7.6.3.1 Key Country Dynamics
7.6.3.2 Competitive Scenario
7.6.3.3 Saudi Arabia Live Cell Encapsulation Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.4 Uae
7.6.4.1 Key Country Dynamics
7.6.4.2 Competitive Scenario
7.6.4.3 Uae Live Cell Encapsulation Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.5 Kuwait
7.6.5.1 Key country dynamics
7.6.5.2 Competitive scenario
7.6.5.3 Kuwait live cell encapsulation market estimates and forecast, 2018-2030 (USD million)
Chapter 8 Competitive Landscape
8.1 Participant’s Overview
8.1.1 AUSTRIANOVA
8.1.2 MERCK KGAA
8.1.3 SPHERE FLUIDICS LIMITED
8.1.4 VIACYTE, INC.
8.1.5 BLACKTRACE HOLDINGS LTD (DOLOMITE MICROFLUIDICS)
8.1.6 BIO INX
8.1.7 LIVING CELL TECHNOLOGIES LIMITED
8.1.8 SIGILON THERAPEUTICS, INC.
8.1.9 ISOGEN
8.1.10 DIATRANZ OTSUKA LTD
8.2 Financial Performance
8.3 Participant Categorization
8.3.1 Market Leaders
8.3.1.1 Live Cell Encapsulation Market Share Analysis, 2022
8.3.2 Strategy Mapping
8.3.2.1 Expansion
8.3.2.2 Acquisition
8.3.2.3 Collaborations
8.3.2.4 Product/service launch
8.3.2.5 Partnerships
8.3.2.6 Others
|
| ※본 조사보고서 [세계의 생세포 캡슐화 시장 (2023-2030) : 폴리머 종류별 (천연, 합성), 용도별 (약물 전달, 세포 이식), 방법별, 지역별] (코드 : GRV23MR113) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 생세포 캡슐화 시장 (2023-2030) : 폴리머 종류별 (천연, 합성), 용도별 (약물 전달, 세포 이식), 방법별, 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
